Lumito AB (NGM:LUMITO) EPS without NRI: kr-17.80 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NGM:LUMITO Lumito AB NGM:LUMITO
18 GF Score
Price kr2.09
! 2 Warning Signs
View Full Analysis

What is Lumito AB EPS without NRI?

Lumito AB NGM:LUMITO -7.24% 18 EPS without NRI is kr-17.80 as of Mar. 2026. GuruFocus rates NGM:LUMITO with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 158 Medical Diagnostics & Research companies, Lumito AB ranks worse than 87.34% on this metric.

Lumito AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was kr-2.38. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was kr-17.80.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Lumito AB's EPS without NRI or its related term are showing as below:

NGM:LUMITO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.8   Med: -18.4   Max: 15.9
Current: -23.2

NGM:LUMITO's 3-Year EPS without NRI Growth Rate is ranked worse than
87.34% of 158 companies
in the Medical Diagnostics & Research industry
Industry Median: 11.1 vs NGM:LUMITO: -23.20

Lumito AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr-2.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-17.80.

Lumito AB's EPS (Basic) for the three months ended in Mar. 2026 was kr-2.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-17.80.


Lumito AB  (NGM:LUMITO) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lumito AB EPS without NRI Related Terms


Lumito AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Lumito AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumito AB EPS without NRI Chart

Lumito AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only -43.14 -18.83 -17.97 -70.36 -35.18

Lumito AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.75 -5.75 -5.75 -3.91 -2.38

NGM:LUMITO vs TMO, DHR, IDXX: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Lumito AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumito AB PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumito AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Lumito AB's PE Ratio without NRI falls into.


NGM:LUMITO
18GF Score
Lumito AB NGM:LUMITO
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumito AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-17.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of kr-17.80 mean?
Lumito AB (NGM:LUMITO) has a EPS without NRI of kr-17.80 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Lumito AB and its competitors. According to the industry distribution chart, Lumito AB ranks #138 out of 158 companies in the Medical Diagnostics & Research industry, placing it in the top 87.3%.
Is Lumito AB's EPS without NRI too high?
Lumito AB's current EPS without NRI is kr-17.80. Based on the distribution chart, Lumito AB ranks #138 out of 158 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Lumito AB has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Lumito AB's EPS without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumito AB ranks #138 out of 158 companies for EPS without NRI. This places Lumito AB in the lower half of its industry. The industry median EPS without NRI is 11.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 11.10, based on 158 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Lumito AB and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumito AB's current EPS without NRI is kr-17.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumito AB stock overvalued right now?
Lumito AB (NGM:LUMITO) has a current EPS without NRI of kr-17.80. The current EPS without NRI is kr-17.80. Lumito AB's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Lumito AB (NGM:LUMITO), the current EPS without NRI is kr-17.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lumito AB Business Description

Address Scheelevagen 19, Lund, SWE, 223 63
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed the next-generation tissue analysis system, based on upconverting nanoparticles (UCNPs). Lumito SCIZYS is a cutting-edge, high-sensitivity system combining labeling and imaging technologies to locate and measure biomarkers in tissue samples. The company holds a broad patent portfolio of three patent families. Lumito's solution enables quantitative and objective assessment of tissue samples, addressing a multitude of challenges in drug development and academic research.
18GF Score

Get the complete analysis for NGM:LUMITO

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.09
Price